Iodine

Iodine Commodity Market Dynamics Intelligence Analysis (July 2026)

I. Recent Price Trends
1. Domestic Market Quotations
- Business Society Benchmark Price as of June 23, 2026: RMB 640.00/kg (stable for multiple consecutive days)
- Significant regional price variation:
- Jiangsu Province: RMB 587,000/ton (99.7% purity)
- Shandong Province: RMB 630,000/ton (99% purity, imported iodine)
- Shandong Tuku Brand Block Iodine: RMB 560,000/ton (99% purity)
- Low-purity by-product iodine: RMB 20/ton (spot availability in Guangzhou, Guangdong—extremely low price reflecting waste-recycling market)

2. Price Volatility Characteristics
- High-purity pharmaceutical-grade iodine prices remain at elevated levels; industrial-grade iodine prices are supported by import costs.
- Prices were unchanged month-on-month in June, but rose 33.3% year-on-year compared to June 2025 (approximately RMB 472,660/ton).

II. Market Driving Factor Analysis
1. Supply-Side Factors
- Import Dependence: China’s domestic iodine resources are scarce. In 2024, imports totaled approximately 7,800 tons (a 5.7% increase year-on-year), primarily sourced from:
- Chile (65%): Industrial-grade iodides
- Japan (22%): Pharmaceutical- and electronics-grade high-purity iodine
- Domestic Production Capacity: Enterprises such as Shandong Haihua and Jiangxi Jiuer Salt Industry account for 80% of national capacity; however, raw material supply remains heavily reliant on seaweed extraction or imported brine.
- Environmental Regulation Pressure: Traditional acid-based iodine extraction processes face restrictions due to wastewater discharge regulations; the adoption of advanced technologies—including membrane separation and biological enrichment—is driving up production costs.

2. Demand-Side Factors
- Pharmaceutical Iodine: The Chinese pharmaceutical iodine market reached RMB 1.23 billion in 2025 and is projected to exceed RMB 1.65 billion by 2030.
- Core Applications: Disinfectants (650 tons/year pure iodine demand), contrast agents (e.g., iohexol), and thyroid disease therapeutics.
- Emerging Applications: Iodine-based nanomaterials and smart controlled-release dressings now collectively account for 15% of the pharmaceutical segment.
- Industrial Demand: LCD panels (accounting for 20% of global iodine demand), dyes, and feed additives show steady growth.
- Iodized Salt: National iodized salt coverage remains consistently above 95%; however, non-iodized salt policies have been implemented in high-iodine regions.

3. Policy Impact
- Salt Monopoly System: State-mandated iodization standards for edible salt ensure stable baseline demand.
- Pharmaceutical Regulation: GMP requirements stipulate ≥99.8% purity for pharmaceutical-grade iodine, accelerating industry upgrading toward high-end products.
- Trade Policy: U.S.–China trade friction has caused tariff volatility for certain imported iodides, though major suppliers—including Chile and Japan—have remained largely unaffected.

III. Competitive Landscape and Key Players
1. Major Domestic Producers
- Shandong Haihua: Leads national seaweed-derived iodine production, leveraging Beihai Salt Field resources.
- Jiangxi Jiuer Salt Industry: Technologically advanced in brine-derived iodine extraction, with significant cost advantages.
- Inner Mongolia Lantai Industrial: Achieves the highest iodine recovery rate in the industry through comprehensive utilization of salt lake resources.

2. International Suppliers
- SQM (Chile): World’s largest iodine producer, controlling over 40% of global iodine resources.
- Tosoh Corporation (Japan): Dominates the semiconductor market with monopoly-level supply of ultra-high-purity electronic-grade iodine.

3. Pricing Dynamics
- Importers secure Chilean and Japanese supplies via long-term contracts, placing cost pressure on smaller domestic producers.
- The pharmaceutical iodine market exhibits high concentration: the top three domestic enterprises command 60% market share, granting them strong pricing power.

IV. Future Trend Outlook (2026–2027)
1. Price Forecast
- Short Term: The benchmark price of RMB 640/kg is expected to remain stable through end-2026, with fluctuations likely limited to 8% in pharmaceutical-grade iodine demand
- Higher production costs arising from environmental technology upgrades

2. Supply–Demand Structural Shifts
- Supply: Domestic enterprises are accelerating deployment of automated seaweed-extraction iodine production lines; national capacity is forecast to grow by 12% by 2027.
- Demand:
- Pharmaceutical iodine’s share of total demand will increase from 55% to 60%.
- Industrial iodine demand—boosted by new energy applications (e.g., iodides in photovoltaic silver paste)—is expected to grow by 15%.

3. Industry Risks
- Resource Security: Political instability in Chile may disrupt supply continuity.
- Technology Substitution: Transition of X-ray contrast agents toward non-iodinated alternatives could erode core demand.
- Policy Changes: Adjustments to national iodized-salt policy may impact baseline consumption volumes.

V. Investment Recommendations
1. Upstream Resources: Prioritize investment opportunities in Chilean mining assets and companies specializing in iodine recovery technologies.
2. Midstream Production: Focus capital allocation on pharmaceutical iodine production capacity—particularly high-purity and nano-grade product lines.
3. Downstream Applications: Target high-growth niches including contrast agents and smart wound dressings, while avoiding intensively competitive traditional industrial iodine markets.